Carboplatin inhibits NSCLC growth and is associated with alterations in HMGB1 expression and macrophage polarization
This study demonstrates that carboplatin inhibits non-small cell lung cancer growth and modulates macrophage polarization, at least in part, by suppressing the HMGB1/RAGE signaling axis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer remains one of the most formidable challenges in modern medicine, claiming more lives than any other form of the disease. While doctors have developed powerful tools to fight it, including surgery, radiation, and drugs that target specific genetic flaws, a significant hurdle remains: the cancer often learns to resist treatment. Among the most common types of lung cancer, known as non-small cell lung cancer, doctors frequently rely on a class of drugs called platinum-based chemotherapy. These drugs work by damaging the DNA inside cancer cells, effectively stopping them from dividing and causing them to die. However, the cancer cells sometimes find ways to survive this assault, and the drugs can also cause severe side effects. To improve outcomes, scientists are looking deeper into the microscopic world surrounding the tumor, specifically at the immune cells that live there. One of the most important of these immune cells is the macrophage, a type of white blood cell that patrols the body. These cells can act in two very different ways: some fight the cancer, while others, often called the "M2" type, actually help the tumor grow and hide from the immune system. Understanding how these cells change their behavior is key to finding new ways to help chemotherapy work better.
In a recent study, researchers set out to investigate a specific protein called HMGB1, which acts as a distress signal when cells are damaged. Under normal conditions, this protein stays safely inside the nucleus of a cell, helping to organize DNA. But when a cell is under stress or dies, HMGB1 leaks out into the surrounding environment. Once outside, it acts like a warning flare, alerting the immune system. The researchers focused on how this protein interacts with a receptor on the surface of immune cells called RAGE. They wanted to see if the amount of HMGB1 present in the tumor environment influenced how macrophages behaved and whether this interaction affected how well carboplatin, a common chemotherapy drug, could kill lung cancer cells. The team worked with human lung cancer cells in a lab dish and also used a mouse model to observe what happened inside a living body. They manipulated the levels of HMGB1, creating groups where the protein was either removed or made in excess, and then treated these groups with carboplatin to see how the cancer cells responded.
The experiments revealed that HMGB1 plays a significant role in how aggressive the cancer cells are. When the researchers increased the amount of HMGB1 in the cancer cells, the cells grew faster and were less likely to die, even when exposed to the chemotherapy drug. Conversely, when they reduced the levels of HMGB1, the cancer cells grew more slowly and became much more sensitive to the treatment, dying at higher rates. This suggested that high levels of this protein help the cancer resist the drug. The study also looked at what happened to the immune cells. The researchers found that when HMGB1 levels were high, the macrophages in the tumor environment tended to shift toward the type that helps the cancer grow. However, when HMGB1 was reduced, or when the cells were treated with carboplatin, the macrophages shifted toward the type that fights the cancer. This shift was linked to the interaction between HMGB1 and the RAGE receptor; when the researchers blocked this interaction or reduced HMGB1, the immune cells were more likely to take on an anti-cancer role.
To confirm these findings, the team moved from the lab dish to a living model. They grew lung tumors in mice and treated them with carboplatin, either alone or in combination with genetic changes that increased HMGB1 levels. The results mirrored what they saw in the lab. The mice treated with carboplatin alone showed significant tumor shrinkage and increased cell death. However, in the mice where HMGB1 was overproduced, the drug was less effective, and the tumors continued to grow larger. The researchers observed that the presence of excess HMGB1 seemed to blunt the power of the chemotherapy, allowing the cancer to survive and the immune system to be less effective. They also noted that the protein HMGB1 and the receptor RAGE were found close to each other in the tumor tissue, supporting the idea that they work together to influence the outcome.
The study concludes that HMGB1 is not just a passive marker of cell damage but an active player in how lung cancer responds to treatment. It appears that when cancer cells are stressed by chemotherapy, they release HMGB1, which can then bind to RAGE on nearby immune cells. This interaction seems to encourage the immune cells to adopt a protective stance toward the tumor rather than an attacking one, and it helps the cancer cells survive the drug. By reducing the levels of HMGB1, the researchers found they could make the cancer cells more vulnerable to carboplatin and encourage the immune system to fight back. While the study does not yet offer a new treatment for patients, it provides a clear map of a mechanism that could be targeted in the future. The findings suggest that combining chemotherapy with strategies to block HMGB1 or its interaction with RAGE might help overcome drug resistance and improve survival for people with lung cancer. The work highlights the complex conversation between cancer cells and the immune system, showing that the success of a drug depends not just on the drug itself, but on how the tumor environment reacts to it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.